ActiGraph Partners With PDH
ActiGraph has officially partnered with Precision Digital Health (PDH).
PDH is joining ActiGraph’s Accelerant™ partnership program, designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. PDH’s platform aggregates participant data from multiple sources, such as ActiGraph’s wearable DHTs, to provide clinical insights to multi-disciplinary teams. This partnership will enable PDH to more efficiently present real-time participant journeys and meaningful clinical outcomes to end users.
Reference
ActiGraph Partners with PDH to Advance DHTs in Clinical Research. (2023, April 3).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
